Showing results (411-420 of 531) with videos related to
Sort By:
Pageof 54
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.British Journal of Haematology|March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402Brad S Kahl, Fangxin Hong, Michael E Williams, et al.Blood|May 24, 2003
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantationGinna G Laport, Bruce L Levine, Edward A Stadtmauer, et al.British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.Leukemia|June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targetingLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.Pageof 54